Regulatory & Compliance

NICE Endorses GSK's Blenrep Combo for Multiple Myeloma
Management & Regulatory NICE Endorses GSK's Blenrep Combo for Multiple Myeloma

Multiple myeloma remains a formidable challenge in oncology, known for its relentless cycle of relapse and treatment resistance. This blood cancer, which originates in plasma cells within the bone marrow, continues to affect patients profoundly, with around 6,240 individuals diagnosed annually in

Will Ibtrozi Become the New Standard for ROS1-Positive NSCLC?
Management & Regulatory Will Ibtrozi Become the New Standard for ROS1-Positive NSCLC?

Imagine facing the battle against a form of lung cancer so rare that it affects only about 2% of those diagnosed with non-small cell lung cancer (NSCLC). This is the reality for those with ROS1-positive NSCLC, a disease that could soon see transformative change with the approval of Nuvation Bio's

AI Revolutionizes Drug Development with NVIDIA and IQVIA Partnership
Management & Regulatory AI Revolutionizes Drug Development with NVIDIA and IQVIA Partnership

The pharmaceutical industry, often characterized by lengthy and costly drug development cycles, is on the brink of a revolutionary shift. A strategic partnership between IQVIA, a leader in clinical research services, and NVIDIA, a cutting-edge technology company renowned for AI innovations,

Can GenAI Revolutionize Youth Health Campaigns?
Tech & Innovation Can GenAI Revolutionize Youth Health Campaigns?

Amid growing public health challenges, the introduction of Generative Artificial Intelligence (GenAI) offers a transformative breakthrough in developing youth health campaigns aimed at issues like vaping. GenAI's efficiency has been spotlighted, showing the potential to drastically reduce the time

Paracetamol Batches Recalled Over Contamination Concerns
Management & Regulatory Paracetamol Batches Recalled Over Contamination Concerns

Chelonia Healthcare Limited has issued a recall for two specific batches of Paracetamol 500mg tablets upon the guidance of the Medicines and Healthcare Regulatory Authority (MHRA). This action arises from reports by healthcare professionals who identified discolored tablets in some of the packages.

Will Aumseqa Revolutionize NSCLC Treatment with EGFR Mutation?
Management & Regulatory Will Aumseqa Revolutionize NSCLC Treatment with EGFR Mutation?

In the rapidly evolving landscape of cancer treatments, Aumseqa (aumolertinib) has emerged as a promising advancement against non-small cell lung cancer (NSCLC) characterized by EGFR mutations. Recently approved by the Medicines and Healthcare products Regulatory Agency (MHRA), Aumseqa is

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later